|
EP1882698A1
|
|
Design of interferon-inducible protein-10 (IP10 or CXCL10) chemokine analogs for the treatment of human diseases
|
|
CN101200502A
|
|
Design of interferon-inducible protein-10 (IP10 or CXCL10) chemokine analogs for the treatment of human diseases
|
|
WO2007079460A2
|
|
Design of cxc chemokine analogs for the treatment of human diseases
|
|
AU2006252080A1
|
|
Design of interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
|
|
JP2008031143A
|
|
Design of interferon-inducible protein-10 (ip10 or cxcl10) chemokine analogs for the treatment of human diseases
|
|
WO2007053952A1
|
|
Platelet factor-4 (pf-4) analogs and their use
|
|
CA2564924A1
|
|
Design of interferon-inducible protein-10 (ip-10 or cxcl10) chemokine analogs for the treatment of human diseases
|
|
US2007116669A1
|
|
Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases
|
|
US2007225216A1
|
|
Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
|
|
BRPI0504758A
|
|
Interleukin-8 mimetics and methods for using them in the prevention, treatment, diagnosis, and amelioration of disease symptoms
|
|
AU2003279715A1
|
|
Design of chemokine analogs for the treatment of human diseases
|
|
US7091310B2
|
|
Chemokine analogs for the treatment of human disease
|
|
WO02094270A2
|
|
Mip-1 alpha receptor ligands - drugs for t-cell mediated and autoimmune diseases
|
|
WO02069961A1
|
|
Il-8 receptor ligands-drugs for inflammatory and autoimmune diseases
|
|
AU1573702A
|
|
Therapeutics for chemokine mediated diseases
|
|
US6831101B2
|
|
Tricyclic rantes receptor ligands
|
|
US6693134B2
|
|
Bicyclic aromatic chemokine receptor ligands
|
|
CA2405907A1
|
|
Cxcr4 agonist treatment of hematopoietic cells
|
|
CA2335109A1
|
|
Cxcr4 agonist treatment of hematopoietic cells
|
|
CA2330350A1
|
|
Therapeutics for chemokine mediated diseases
|
